Calls
1
u/GenFokoff
Reddit r/wallstreetbets
Win Rate
100.0%
return
+53.6%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 19
$5.52
+53.6%
The author argues IBRX is first with an FDA-approved NK-cell immune activator, Anktiva, already in clinical use as a combination therapy in oncology. The addressable opportunity spans multiple cancer types, and other companies entering the space validate the mechanism rather than threaten it. The author frames this as a long-term case where medical fundamentals may be ahead of market awareness, not a short-term trade.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/GenFokoff has 1 trade ideas tracked on Buzzberg across 1 tickers since January 2026. Most covered: IBRX.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
